3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
66
Carcinoma, Non-Small-Cell Lung
39
Breast Neoplasms
32
Triple Negative Breast Neoplasms
25
Neoplasm Metastasis
18
Neoplasms
15
Lung Neoplasms
15
Colorectal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
8
Stomach Neoplasms
6
Ovarian Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Head and Neck Neoplasms
5
Gallbladder Neoplasms
5
Fallopian Tube Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Adenocarcinoma
5
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Pancreatic Ductal
4
Carcinoma
4
Neoplasms by Site
3
Gastrointestinal Neoplasms
3
Endometrial Neoplasms
3
Brain Neoplasms
3
Biliary Tract Neoplasms
3
Vaccinia
2
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Temozolomide
1
Tablets
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
130-nm albumin-bound paclitaxel
×
1 year
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled